ATE325618T1 - Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb - Google Patents

Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb

Info

Publication number
ATE325618T1
ATE325618T1 AT00901331T AT00901331T ATE325618T1 AT E325618 T1 ATE325618 T1 AT E325618T1 AT 00901331 T AT00901331 T AT 00901331T AT 00901331 T AT00901331 T AT 00901331T AT E325618 T1 ATE325618 T1 AT E325618T1
Authority
AT
Austria
Prior art keywords
growth factor
nerve growth
diseases
treatment
production
Prior art date
Application number
AT00901331T
Other languages
English (en)
Inventor
Alessandro Lambiase
Original Assignee
Anabasis S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anabasis S R L filed Critical Anabasis S R L
Application granted granted Critical
Publication of ATE325618T1 publication Critical patent/ATE325618T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00901331T 1999-01-29 2000-01-21 Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb ATE325618T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000069A IT1305294B1 (it) 1999-01-29 1999-01-29 Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.

Publications (1)

Publication Number Publication Date
ATE325618T1 true ATE325618T1 (de) 2006-06-15

Family

ID=11406408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901331T ATE325618T1 (de) 1999-01-29 2000-01-21 Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb

Country Status (11)

Country Link
US (3) US9468665B1 (de)
EP (1) EP1161256B1 (de)
AT (1) ATE325618T1 (de)
AU (1) AU2129200A (de)
CY (1) CY1106140T1 (de)
DE (1) DE60027878T2 (de)
DK (1) DK1161256T3 (de)
ES (1) ES2264416T3 (de)
IT (1) IT1305294B1 (de)
PT (1) PT1161256E (de)
WO (1) WO2000044396A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
EP1891966B1 (de) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation der Neurotrophinaktivität;Screeningsverfahren
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
IT1396607B1 (it) 2009-11-16 2012-12-14 Hmfra Hungary Ltd Liability Company Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso.
IT202000032423A1 (it) 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE382477C (de) 1923-10-03 Willy Pietzsch Vorrichtung zum Versenken von Schreibmaschinen in Schreibmaschinentischen, bei der die Schreibmaschine in wagerechter Lage nach einem seitlich in anderer Hoehenlage befindlichen Standplatz auf und ab bewegt wird
US4959319A (en) 1985-08-01 1990-09-25 Skelnik Debra L Process of corneal enhancement
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
DE3827477A1 (de) 1988-08-12 1990-02-22 Biotechnolog Forschung Gmbh Verfahren zur isolierung und zur alleinigen zuechtung von endothelialzellen der menschlichen hornhaut (hcec)
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US5641479A (en) 1991-02-12 1997-06-24 Richardson-Vicks Inc. Cosmetic compositions comprising an imidazolium derivative and branched polyethylene glycol
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1255657B (it) 1992-05-29 1995-11-09 Colture di tessuto di mucosa congiuntivale differenziata, procedimentoper la loro preparazione e supporti per il loro uso.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
CA2265743A1 (en) 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
JPH10218787A (ja) * 1997-02-06 1998-08-18 Akio Okamoto 神経栄養因子による眼科用組成物
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
AU8559398A (en) 1998-08-05 2000-02-28 Advanced Medicine Research Institute Remedies for cerebral central lesions with the use of neurotrophic factors
EP1135105B1 (de) 1998-12-09 2005-03-02 Chiron Corporation Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US20020009498A1 (en) 1999-11-05 2002-01-24 Guy L. Clifton Methods and compositions for treatment of traumatic brain injury
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing

Also Published As

Publication number Publication date
CY1106140T1 (el) 2011-06-08
US20120142591A1 (en) 2012-06-07
DE60027878T2 (de) 2007-04-19
US9345749B2 (en) 2016-05-24
WO2000044396A1 (en) 2000-08-03
ES2264416T3 (es) 2007-01-01
ITRM990069A1 (it) 2000-07-29
EP1161256B1 (de) 2006-05-10
AU2129200A (en) 2000-08-18
US20170007670A1 (en) 2017-01-12
US9468665B1 (en) 2016-10-18
US10010586B2 (en) 2018-07-03
PT1161256E (pt) 2006-09-29
IT1305294B1 (it) 2001-05-04
EP1161256A1 (de) 2001-12-12
DE60027878D1 (de) 2006-06-14
DK1161256T3 (da) 2006-09-18

Similar Documents

Publication Publication Date Title
Cantor et al. Glaucoma in the Maroteaux-Lamy syndrome
ATE325618T1 (de) Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb
KR102256185B1 (ko) 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
DE60129322D1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
DE69028877D1 (de) Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden
O'brien et al. Doryl in the treatment of glaucoma simplex
IT9020968A1 (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
RU2090165C1 (ru) Способ лечения поражений роговицы
DE69614553D1 (de) Aromatische carbonsaürediamide mit antigastrin wirkung, ihre herstellung und pharmazeutische verwendung
RU2163123C2 (ru) Глазные капли
RU2104678C1 (ru) Способ лечения заболеваний глаза
SWAN et al. Dibutoline Sulfate: A New Mydriatic and Cycloplegic Drug
RU2322243C1 (ru) Фармацевтическая композиция для лечения поражений роговицы
LASKY Corneal response to emetine hydrochloride
RU2402303C1 (ru) Способ лечения врастания эпителия
Sichel et al. A case of sympathetic ophthalmitis of unusual onset responding satisfactorily to treatment
RU2131233C1 (ru) Способ лечения глаукомы
RU2314793C2 (ru) Способ получения глазных пленок
Ascher et al. sure experiments dealing with the effects of ischemia upon the retinal function.
RU98119433A (ru) Способ лечения заболеваний роговицы
US20060058345A1 (en) Use of papaverine-like vasodilator and pharmaceutical composition
Crisp Colorado Ophthalmological Society
Citron et al. The use of therapeutic soft contact lenses in corneal disease
Von der Heydt Chicago Ophthalmological Society: February 21, 1944
Polak Drugs used in ocular treatment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1161256

Country of ref document: EP